FDA
-
-
-
-
-
-
-
Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $260 at Oppenheimer
-
-
-
-
-
-
-
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
-
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
-
-
-
-
-
-
-
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill
-
-
-
-
-
-
-
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $76 at Raymond James
-
335,219 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


